Login to Your Account

Start-up Medicortex taking on TBI in dual drug-biomarker approach

By Cormac Sheridan
Staff Writer

Wednesday, March 30, 2016

DUBLIN – Finnish start-up Medicortex Finland Oy is taking on one of the biggest challenges in medicine, the diagnosis and treatment of traumatic brain injury (TBI), with a two-pronged strategy based on the identification and validation of a novel biomarker and on the development of a therapeutic that bundles several mechanisms of action into a single molecule.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription